These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31502039)

  • 1. Efficacy of Dabrafenib for three children with brainstem BRAF
    Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
    J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
    Chamberlain MC
    CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
    Pasqualetti F; Restante G; Gonnelli A; Rofi E; Molinari A; Crucitta S; Paiar F; Rudà R; Danesi R; Soffietti R; Del Re M
    Neuro Oncol; 2019 Dec; 21(12):1610-1611. PubMed ID: 31504796
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
    Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
    Meletath SK; Pavlick D; Brennan T; Hamilton R; Chmielecki J; Elvin JA; Palma N; Ross JS; Miller VA; Stephens PJ; Snipes G; Rajaram V; Ali SM; Melguizo-Gavilanes I
    J Natl Compr Canc Netw; 2016 Nov; 14(11):1345-1350. PubMed ID: 27799506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.
    Donson AM; Kleinschmidt-DeMasters BK; Aisner DL; Bemis LT; Birks DK; Levy JM; Smith AA; Handler MH; Foreman NK; Rush SZ
    Brain Pathol; 2014 Mar; 24(2):173-83. PubMed ID: 24238153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas.
    Chen X; Pan C; Zhang P; Xu C; Sun Y; Yu H; Wu Y; Geng Y; Zuo P; Wu Z; Zhang J; Zhang L
    J Clin Neurosci; 2017 Dec; 46():50-57. PubMed ID: 28986151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
    Yau WH; Ameratunga M
    J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status.
    Lindsay AJ; Rush SZ; Fenton LZ
    J Neurooncol; 2014 Jun; 118(2):395-404. PubMed ID: 24792487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
    Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
    J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
    Chatterjee D; Garg C; Singla N; Radotra BD
    Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brainstem gangliogliomas: prognostic factors, surgical indications and functional outcomes.
    Pan CC; Chen X; Xu C; Wu WH; Zhang P; Wang Y; Wu T; Tang J; Xiao XR; Wu Z; Zhang JT; Zhang LW
    J Neurooncol; 2016 Jul; 128(3):445-53. PubMed ID: 27112924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib in the treatment of advanced melanoma.
    Medina T; Amaria MN; Jimeno A
    Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
    del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
    J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.